Comparison of the efficiency of 1st and 3rd generation plasmids encoding a chimeric T-cell receptor for a tumor marker of ovarian cancer

Ovarian cancer is the fifth most common cause of cancer death in women and the second most commonly diagnosed tumor in gynecology. The search for new effective methods of treating ovarian cancer is an urgent clinical task. One of the most promising methods today is immunotherapy with CAR-T technology. The CA125 antigen, which is highly expressed in ovarian cancer, may be a target in the development of these therapies. This work presents the results of the development of a method for CAR-T therapy for ovarian cancer with plasmid constructs carrying the genes of monomolecular T-cell receptors for CA125. Three plasmid variants were developed and synthesized, experimental studies showed the correctness and efficiency of assembly of T-cell receptors for CA125 after transfection of cells with plasmid constructs. The efficiency of binding of genetically modified cells to the dissolved form of CA125 was demonstrated. The chimeric construct 28 p3CA2 (epitope X181) appeared to be more efficient (72% of transfected T-lymphocytes acquire the ability to bind CA125) and more promising for further research.